SCHEMBL7033159

SCHEMBL7033159

O=C(/C=C/c1ccnc2ccccc12)c1cc(Cl)ccc1Cl

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.55
ALDH1A1 P00352 5/20 0.55
HTT P42858 3/20 0.55
NPC1 O15118 3/20 0.55
RAB9A P51151 3/20 0.55
SMN1; SMN2 Q16637 2/20 0.55
HSP90AA1 P07900 1/20 0.55
ATM Q13315 1/20 0.55
NPSR1 Q6W5P4 1/20 0.55
KDM4E B2RXH2 5/20 0.52
KMT2A Q03164 5/20 0.52
MEN1 O00255 3/20 0.52
HPGD P15428 2/20 0.52
CYP1A2 P05177 1/20 0.52
CYP2C9 P11712 1/20 0.52
ALOX15 P16050 1/20 0.52
CYP2C19 P33261 1/20 0.52
HSD17B10 Q99714 1/20 0.52
MAPK1 P28482 1/20 0.52
L3MBTL1 Q9Y468 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7033164 1.00 MAPT (0.55) MAPTALDH1A1HTTNPC1RAB9A
SCHEMBL10112866 0.77 RECQL (0.47) ALDH1A1HTTNPC1RAB9ASMN1; SMN2
SCHEMBL2385787 0.74 MAPT (0.62) MAPTALDH1A1HTTNPC1RAB9A
SCHEMBL2385781 0.74 MAPT (0.62) MAPTALDH1A1HTTNPC1RAB9A
SCHEMBL10309025 0.74 MAPT (0.66) MAPTALDH1A1HTTNPC1RAB9A
SCHEMBL10275186 0.74 MAPT (0.66) MAPTALDH1A1HTTNPC1RAB9A
SCHEMBL11796726 0.73 MAPT (0.60) MAPTALDH1A1HTTNPC1RAB9A
SCHEMBL11796720 0.73 MAPT (0.60) MAPTALDH1A1HTTNPC1RAB9A
SCHEMBL10309030 0.71 MAPT (0.60) MAPTALDH1A1HTTNPC1RAB9A
SCHEMBL10275200 0.71 MAPT (0.60) MAPTALDH1A1HTTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2002048097-A9 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS CORVAS INT INC (US) 2003-05-08 WO claimed
WO-2002048097-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS CORVAS INTERNATIONAL, INC. (US) 2002-06-20 WO claimed
WO-2013036766-A1 SMALL MOLECULE NAPHTHOQUINONE- AND PHTHALIMIDE-BASED LIPOCATIONS AS ANTI-PARASITIC AGENTS UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC. (US) 2013-03-14 WO disclosed
WO-2002048097-A9 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS CORVAS INT INC (US) 2003-05-08 WO disclosed
US-20020107266-A1 Compounds, compositions and methods for treatment of parasitic infections DENDREON CORPORATION 2002-08-08 US disclosed
WO-2002048097-A1 COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATMENT OF PARASITIC INFECTIONS CORVAS INTERNATIONAL, INC. (US) 2002-06-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107266-A1 Compounds, compositions and methods for treatment of parasitic infections CAT, CTSA, CTRL MAPT 2326/4885ALDH1A1 2678/4885HTT 2584/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.